Drugs / ZEMIRCICLIB
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03263637 | Oct 2017 → Sep 2021 | Richter transformation, T-cell non-Hodgkin lymphoma, acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma +4 | AstraZeneca | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04630756 | Feb 2021 → Sep 2023 | hematopoietic and lymphoid cell neoplasm | AstraZeneca | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05140382 | Dec 2021 → Aug 2023 | classic Hodgkin lymphoma, peripheral T-cell lymphoma, not otherwise specified | AstraZeneca | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-05-16 | AstraZeneca | Results AstraZeneca showcases scientific advances across rare and malignant haematological conditions at EHA 2023 astrazeneca.com ↗
Efficacy and safety results from a Phase IIa study looking at the CDK9 inhibitor, AZD4573, in patients with relapsed or refractory PTCL will show encouraging clinical activity as a monotherapy, including three CRs and one complete metabolic response after initial progressive disease. |
| 2018-04-04 | AstraZeneca | Results AstraZeneca’s early and late-stage oncology portfolio showcased at AACR annual meeting and ELCC astrazeneca.com ↗
Data on AZD4573, a CDK9 inhibitor, will demonstrate rapid cell-death induction in haematological tumour models through depletion of MCL1 (Abstract #310/17). |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-05-16 | AstraZeneca | AstraZeneca showcases scientific advances across rare and malignant haematological conditions at EHA 2023 astrazeneca.com ↗ |
| 2018-04-04 | AstraZeneca | AstraZeneca’s early and late-stage oncology portfolio showcased at AACR annual meeting and ELCC astrazeneca.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZEMIRCICLIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4462530 ↗ |
| Known as | AZD4573 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04630756 ↗ |
| Action | Inhibit | “AZD4573 is a highly selective and potent CDK9 inhibitor.” PMID 31699827 ↗ Nov 2019 |
| Modality | Small molecule | — CHEMBL4462530 ↗ |
| Route | Intravenous | “AZD4573 will be administered as a intravenous (IV) infusion.” NCT03263637 ↗ |
| Target | CDK9 | “AZD4573 is a highly selective and potent CDK9 inhibitor.” PMID 31699827 ↗ Nov 2019 |